The HIV glycan shield as a target for broadly neutralizing antibodies
about
Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and ImmunityNatively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding siteArms Race between Enveloped Viruses and the Host ERAD MachineryComposition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope GlycoproteinRecent Insights into the HIV/AIDS Pandemic.HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual.Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman PrimatesGlycan-protein interactions in viral pathogenesisStructure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodiesMapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding.Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer.HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.Broadly Neutralizing Antibody-Guided Carbohydrate-Based HIV Vaccine Design: Challenges and Opportunities.Myeloid C-Type Lectin Receptors in Viral Recognition and Antiviral Immunity.Structural principles controlling HIV envelope glycosylation.Dengue Virus Glycosylation: What Do We Know?Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer.Short Communication: Manα1-2Man-Binding Anti-HIV Lectins Enhance the Exposure of V2i and V3 Crown Neutralization Epitopes on the V1/V2 and V3 Hypervariable Loops of HIV-1 Envelope.Insights from NMR Spectroscopy into the Conformational Properties of Man-9 and Its Recognition by Two HIV Binding Proteins.X-ray and EM structures of a natively glycosylated HIV-1 envelope trimer.Bacterially derived synthetic mimetics of mammalian oligomannose prime antibody responses that neutralize HIV infectivity.Site-Selective Chemoenzymatic Glycosylation of an HIV-1 Polypeptide Antigen with Two Distinct N-Glycans via an Orthogonal Protecting Group Strategy.Signal peptide of HIV envelope protein impacts glycosylation and antigenicity of gp120.Full-Genome Characterization and Genetic Evolution of West African Isolates of Bagaza Virus.Coupling of Single Molecule, Long Read Sequencing with IMGT/HighV-QUEST Analysis Expedites Identification of SIV gp140-Specific Antibodies from scFv Phage Display Libraries.Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.HIV Entry and Its Inhibition by Bifunctional Antiviral Proteins
P2860
Q27654848-17E2F753-6E29-4762-B259-D9F87B259311Q27728037-C8A076E5-8A36-485A-AB92-29D1FF5FAF21Q28078319-500AD61D-ED70-4DB4-9DCB-CAE40629A553Q29306052-D6E3F20D-E919-4C4A-A247-49DFA2205A94Q30235024-FDE641E6-A813-414F-B8D8-AA611A7ECD22Q30393763-3E5BE6B8-F1BC-441C-96BE-1D28C26906D1Q33612459-5B7AC811-D436-47DF-B428-CD5D3246C8D8Q33926161-FC3B3049-054C-42D8-A897-DA4AEEDCEA8AQ36246403-BA6FA8E1-DF30-4CAA-9F82-6A5D4CCADC51Q36531018-55171F82-F608-4139-AFCA-F8AC720E90A4Q37240035-2A72A08E-A9F8-47DE-907A-BB63E140A1D4Q38290294-15A59E50-E062-4A54-B10C-830054747FBFQ38665463-DA7B2352-0B8E-4395-90C3-3CB37A7F7096Q38673539-F2E22E4E-01D5-4D44-9EE9-9CF37CF73C8BQ38695294-3769A24B-5C6C-4B39-979F-A3A505BE55A6Q39192653-7A6E4EFC-618B-44F1-9943-4FBA13170C3BQ39211319-51114F00-CC66-4812-A60E-5F1E15EB5857Q40044088-94A88290-2AEA-4DA9-9EDF-35F7C6F7B0CBQ40061438-1739D1BC-8352-4752-B1E5-BE4C8002DD6AQ40286498-950AB012-BB5B-423F-929A-B839576673D4Q40343366-020C42B0-C067-46B1-B541-F1B6F6C64B3EQ41989259-A34C500B-BC49-456D-8694-C83D71686488Q46226616-9AC8F46E-030D-4C75-92ED-3BAD3ACEB46EQ47098665-0114AB48-E9EB-4236-88D2-FB7181A46058Q49790276-F6F0D6CD-8094-4934-8B37-8398E40927BCQ52589934-81D41A44-34EE-44A4-9004-8910FB69CDF1Q52653118-F6488DE6-90D6-41F0-86C0-0F7630C28704Q53689028-19C2898E-A7C7-4248-9052-0E14F91A261FQ58555325-FB419F06-7AC4-4B78-B2CC-CD6EF1CC7F21
P2860
The HIV glycan shield as a target for broadly neutralizing antibodies
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The HIV glycan shield as a target for broadly neutralizing antibodies
@ast
The HIV glycan shield as a target for broadly neutralizing antibodies
@en
The HIV glycan shield as a target for broadly neutralizing antibodies
@nl
type
label
The HIV glycan shield as a target for broadly neutralizing antibodies
@ast
The HIV glycan shield as a target for broadly neutralizing antibodies
@en
The HIV glycan shield as a target for broadly neutralizing antibodies
@nl
prefLabel
The HIV glycan shield as a target for broadly neutralizing antibodies
@ast
The HIV glycan shield as a target for broadly neutralizing antibodies
@en
The HIV glycan shield as a target for broadly neutralizing antibodies
@nl
P2860
P921
P3181
P356
P1433
P1476
The HIV glycan shield as a target for broadly neutralizing antibodies
@en
P2093
Katie J Doores
P2860
P304
P3181
P356
10.1111/FEBS.13530
P407
P577
2015-12-01T00:00:00Z